Neurobiology of Aging
Volume 27, Issue 7 , Pages 926-932 , July 2006

Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy

  • Antonio Metastasio

      Affiliations

    • Institute of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Via Brunamonti 51, 06122 Perugia, Italy
    • ,
  • Patrizia Rinaldi

      Affiliations

    • Institute of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Via Brunamonti 51, 06122 Perugia, Italy
    • ,
  • Roberto Tarducci

      Affiliations

    • Department of Medical Physics, Perugia Hospital, Via Brunamonti 51, 06122 Perugia, Italy
    • ,
  • Elena Mariani

      Affiliations

    • Institute of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Via Brunamonti 51, 06122 Perugia, Italy
    • ,
  • Filippo T. Feliziani

      Affiliations

    • Institute of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Via Brunamonti 51, 06122 Perugia, Italy
    • ,
  • Antonio Cherubini

      Affiliations

    • Institute of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Via Brunamonti 51, 06122 Perugia, Italy
    • ,
  • Gian Piero Pelliccioli

      Affiliations

    • Department of Neuroradiology, Perugia Hospital, Via Brunamonti 51, 06122 Perugia, Italy
    • ,
  • Gianni Gobbi

      Affiliations

    • Department of Medical Physics, Perugia Hospital, Via Brunamonti 51, 06122 Perugia, Italy
    • ,
  • Umberto Senin

      Affiliations

    • Institute of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Via Brunamonti 51, 06122 Perugia, Italy
    • ,
  • Patrizia Mecocci

      Affiliations

    • Institute of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Via Brunamonti 51, 06122 Perugia, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 075 578 3270; fax: +39 075 573 0259.

Received 16 February 2005 ,Revised 4 April 2005 ,Accepted 1 May 2005.

References 

  1. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet. 2000;355:1696–1697
  2. Arnaiz E, Almkvist O. Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. Acta Neurol Scand Suppl. 2003;179:34–41
  3. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport. 1996;7:1397–1400
  4. Bronge L, Bogdanovic N, Wahlund LO. Postmortem MRI and histopathology of white matter changes in Alzheimer brains. A quantitative, comparative study. Dement Geriatr Cogn Disord. 2002;13:205–212
  5. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion rates. Int Psychogeriatr. 2004;16:129–140
  6. Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA. Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem. 2002;80:91–100
  7. Catani M, Cherubini A, Howard R, Tarducci R, Pel liccioli GP, Piccirilli M, et al. 1H MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport. 2001;12:2315–2317
  8. Catani M, Piccirilli M, Cherubini A, Howard R, Pel liccioli GP, Mariani E, et al. Axonal injury within language network in primary progressive aphasia. Ann Neurol. 2003;53:242–247
  9. Chakraborty G, Mekala P, Yahya D, Wu G, Ledeen RW. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J Neurochem. 2001;78:736–745
  10. Chantal S, Braun CM, Bouchard RW, Labelle M, Boulanger Y. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res. 2004;1003:26–35
  11. Chen JG, Charles HC, Barboriak DP, Doraiswamy PM. Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate. Acta Neurol Scand Suppl. 2000;176:20–26
  12. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology. 2003;60:1374–1377
  13. Dautry C, Vaufrey F, Brouillet E, Bizat N, Henry PG, Conde F, et al. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab. 2000;20:789–799
  14. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145–155
  15. Demougeot C, Garnier P, Mossiat C, Bertrand N, Giroud M, Beley A, et al. N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury. J Neurochem. 2001;77:408–415
  16. Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain. 2002;125:2332–2341
  17. Doraiswamy PM, Charles HC, Krishnan KR. Prediction of cognitive decline in early Alzheimer's disease. Lancet. 1998;352:1678
  18. Drzezga A, Lautenschlager N, Siebner H, Riemnschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104–1113
  19. Estevez-Gonzalez A, Kulisevsky J, Boltes A, Otermin P, Garcia-Sanchez C. Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging. Int J Geriatr Psychiatry. 2003;18:1021–1028
  20. Farber SA, Slack BE, Blusztajn JK. Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease. FASEB J. 2000;14:2198–2206
  21. Firbank MJ, Harrison RM, O’Brien JT. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord. 2002;14:64–76
  22. Firbank MJ, Minett T, O’Brien JT. Changes in DWI and MRS associated with white matter hyperintensities in elderly subjects. Neurology. 2003;61:950–954
  23. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59–66
  24. Heales SJ, Davies SE, Bates TE, Clark JB. Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration. Neurochem Res. 1995;20:31–38
  25. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 2001;21:3017–3023
  26. Huang C, Wahlund LO, Almkvist O, Eleuh D, Svensson L, Jonsson T, et al. Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment. Neuroimage. 2003;19:1137–1144
  27. Huang C, Wahlund LO, Svensson L, Winblad B, Julin P. Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurol. 2002;2:9
  28. Huang W, Alexander GE, Daly EM, Shetty HU, Krasuki JS, Rapoport SI, et al. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study. Am J Psychiatry. 1999;156:1879–1886
  29. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–572
  30. Jack CR, Shiung MM, Gunter JL, O’Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591–600
  31. Janke AL, de Zubicaray G, Rose SE, Griffin M, Chalk JB, Galloway GJ. 4D deformation modeling of cortical disease progression in Alzheimer's dementia. Magn Reson Med. 2001;46:661–666
  32. Jessen F, Block W, Traber F, Keller E, Flacke S, Lamerichs R, et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology. 2001;57:930–932
  33. Jessen F, Block W, Traber F, Keller E, Flacke S, Papassotiropoulos A, et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology. 2000;55:684–688
  34. Kantarci K, Jack CR, Xu YC, Campeau NG, O’Brien PC, Smith GE, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology. 2000;55:210–217
  35. Kitabayashi Y, Ueda H, Tsuchida H, Iizumi H, Narumoto J, Nakamura K, et al. Relationship between regional cerebral blood flow and verbal fluency in Alzheimer's disease. Psychiatry Clin Neurosci. 2001;55:459–463
  36. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004;304:448–452
  37. Madhavarao CN, Chinopoulos C, Chandrasekaran K, Namboodiri MA. Characterization of the N-acetylaspartate biosynthetic enzyme from rat brain. J Neurochem. 2003;86:824–835
  38. Martinez-Bisbal MC, Arana E, Marti-Bonmati L, Molla E, Celda B. Cognitive impairment: classification by 1H magnetic resonance spectroscopy. Eur J Neurol. 2004;11:187–193
  39. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939–944
  40. Miller BL, Chang L, Booth R, Ernst T, Cornford M, Nikas D, et al. In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci. 1996;58:1929–1935
  41. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–1992
  42. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging. 2003;24:915–919
  43. Rose SE, de Zubicaray GI, Wang D, Galloway GJ, Chalk JB, Eagle SC, et al. A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging. 1999;17:291–299
  44. Ross AJ, Sachdev PS. Magnetic resonance spectroscopy in cognitive research. Brain Res Brain Res. 2004;44:83–102
  45. Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Gruetter R. In vivo magnetic resonance spectroscopy of human brain: the biophysical basis of dementia. Biophys Chem. 1997;68:161–172
  46. Selden NR, Gitelman DR, Salamon-Murayama N, Parrish TB, Mesulam MM. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain. 1998;121:2249–2257
  47. Siegel S, Castellan NJ. Non parametric statistics. New York: McGraw-Hill International Edition; 1988;
  48. Simmons A, Smail M, Moore E, Williams SC. Serial precision of metabolite peak area ratios and water referenced metabolite peak areas in proton MR spectroscopy of the human brain. Magn Reson Imaging. 1998;16:319–330
  49. Stewart VC, Heales SJ. Nitric oxide-induced mitochondrial dysfunction: implications for neurodegeneration. Free Radic Biol Med. 2003;34:287–303
  50. Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, et al. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci. 2003;23:994–1005
  51. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology. 2001;56:592–598
  52. Visser PJ, Verhey FR, Hofman PA, Scheltens P, Jolles J. Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry. 2002;72:491–497
  53. Waldman AD, Rai GS. The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study. Neuroradiology. 2003;45:507–512
  54. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, et al. European Task Force on age-related white matter changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318–1322
  55. Watson ME, Welsh-Bohmer KA, Hoffman JM, Lowe V, Rubin DC. The neural basis of naming impairments in Alzheimer's disease revealed through positron emission tomography. Arch Clin Neuropsychol. 1999;14:347–357
  56. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1983;17:37–49
  57. Yesavage JA, O’Hara R, Kraemer H, Noda A, Taylor JL, Ferris S, et al. Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment. J Psychiatr Res. 2002;36:281–286

PII: S0197-4580(05)00117-X

doi: 10.1016/j.neurobiolaging.2005.05.002

Neurobiology of Aging
Volume 27, Issue 7 , Pages 926-932 , July 2006

Article Tools

* Image Usage & Resolution